Currently, the GsMTx4 peptide is the only Piezo1 inhibitor tested in AAA, which has been shown to repress matrix degradation via MMP3 and reduce aortic dilatation in the AngII and elastase-induced AAA mice models (52). Here, PIEZO1 is linked to triple-A syndrome.